Study Highlights Challenges of Adherence in Successful Deployment of PrEP Interventions
March 7, 2012
"Data presented from the FEM-PrEP trial by Dr. Lut Van Damme Tuesday [at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle] highlighted the challenge that adherence plays in successfully deploying effective Pre-Exposure Prophylaxis (PrEP) interventions," HIV Medicine Association Executive Director Andrea Weddle writes in this guest post in the Center for Global Health Policy's "Science Speaks" blog. "The FEM-PrEP study was conducted to evaluate the protective effect of a daily oral dose of emtricitabine/tenofovir disoproxil fumerate (FTC/TDF) among African women, but was halted early, in April 2011," because of "interim data analysis showing similar rates of new HIV infections among women taking daily FTC/TDF and the placebo arm," Weddle notes. Van Damme said blood monitoring did not show levels of the drug consistent with self-reported adherence rates, according to Weddle (3/6).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)